Dr.Β DavidΒ Maloney
MD, PhD
Professor Emeritus, Translational Science & Therapeutics
corporate_fareFred Hutchinson Cancer Center, Seattle
David Maloney
MD, PhD
Dr. David G. Maloney is a physician-scientist at Fred Hutchinson Cancer Center, Seattle, recognised internationally for his contributions to CAR T-cell therapy, monoclonal antibody therapy, and hematopoietic cell transplantation for blood cancers. He holds an MD and PhD from Stanford University and has more than four decades of clinical and research experience in haematologic oncology.
Dr. Maloney's career has centred on developing safer and more effective immune-based therapies for patients with lymphoma, leukaemia, chronic lymphocytic leukaemia, non-Hodgkin lymphoma, and multiple myeloma. He was instrumental in the development and clinical testing of rituximab β the first antibody-based cancer drug to reach the market β which transformed treatment for B-cell malignancies. He subsequently helped establish the Bezos Family Immunotherapy Clinic at Fred Hutch and served as its first medical director, overseeing the delivery of genetically engineered immune cell therapies including CAR T-cell products. He has authored more than 200 peer-reviewed publications and has led multiple clinical trials in cellular immunotherapy and reduced-intensity transplantation. His current academic role is Professor Emeritus in the Translational Science and Therapeutics Division and a member of the Immunotherapy Integrated Research Center at Fred Hutch.
CancerFax can coordinate medical-report review and consultation support for international patients seeking an expert opinion from Dr. Maloney at Fred Hutchinson Cancer Center, subject to appointment availability and case acceptance.
Why Consider Dr. David Maloney?
Dr. Maloney is a globally recognised pioneer in blood cancer immunotherapy, with landmark contributions to rituximab, CAR T-cell therapy, and reduced-intensity transplantation that continue to shape standard-of-care treatment worldwide.
Areas of Specialisation
Advanced immune-based therapies for haematologic malignancies
Dr. Maloney's clinical and research expertise covers the full spectrum of immune-based and cellular therapies for blood cancers, with particular depth in CAR T-cell therapy, antibody-based treatments, and hematopoietic cell transplantation.
CAR T-Cell & Cellular Immunotherapy
Genetically engineered immune cell therapies for relapsed or refractory haematologic malignancies.
- arrow_rightCAR T-cell therapy for eligible patients with leukaemia, lymphoma, and myeloma
- arrow_rightPatient selection, pre-infusion conditioning, and post-infusion monitoring
- arrow_rightClinical trialβbased access to novel CAR T constructs
- arrow_rightMonoclonal antibody therapy including rituximab-based regimens
- arrow_rightAntibody-drug conjugates and radioimmunotherapy approaches
- arrow_rightGraft-versus-tumour immune effect optimisation in transplant settings
Hematopoietic Cell Transplantation
Autologous and allogeneic transplant strategies, including reduced-intensity conditioning regimens.
- arrow_rightAllogeneic stem cell transplantation for haematologic malignancies
- arrow_rightAutologous stem cell transplantation for eligible patients
- arrow_rightReduced-intensity and nonmyeloablative conditioning regimens for CLL, NHL, and myeloma
- arrow_rightStrategies to preserve graft-versus-tumour immunity
- arrow_rightReduction of graft-versus-host disease complications
- arrow_rightPost-transplant immune reconstitution monitoring
Lymphoma, Leukaemia & Myeloma
Specialist management of B-cell and other haematologic malignancies.
- arrow_rightNon-Hodgkin lymphoma β B-cell subtypes including DLBCL and follicular lymphoma
- arrow_rightChronic lymphocytic leukaemia β treatment planning for relapsed and refractory cases
- arrow_rightAntibody and cellular therapy integration into lymphoma management
- arrow_rightMyeloma management including transplant-eligible and transplant-ineligible pathways
- arrow_rightCAR T-cell and antibody-based approaches for relapsed myeloma
Procedures & Treatment Approaches
Clinical services in cellular immunotherapy and blood cancer treatment
Dr. Maloney's clinical practice encompasses the full range of immune-based and transplant-based treatments for haematologic malignancies, from CAR T-cell infusion and stem cell transplantation to antibody therapy and clinical trial enrolment.
CAR T-Cell & Cellular Immunotherapy
Medical OncologyDelivery and oversight of genetically engineered immune cell therapies for eligible blood cancer patients.
Hematopoietic Cell Transplantation
TransplantAutologous and allogeneic transplant programmes with a focus on reduced-intensity conditioning for older or less fit patients.
Antibody-Based Cancer Therapy
Targeted TherapyMonoclonal antibody and antibody-drug conjugate protocols for B-cell malignancies and selected other cancers.
Post-Treatment Monitoring
MonitoringOngoing disease surveillance and immune reconstitution assessment following cellular or transplant therapy.
Second Opinion Consultations
Second OpinionIndependent expert review of diagnosis and treatment planning for patients with complex or relapsed haematologic cancers.
Research & Publications
Landmark contributions to cancer immunotherapy and haematologic oncology
Dr. Maloney has authored more than 200 peer-reviewed publications and led multiple clinical trials in cellular immunotherapy, antibody therapy, and hematopoietic cell transplantation. His work spans foundational discoveries with rituximab to contemporary CAR T-cell therapy programmes.
Dr. Maloney has led clinical trials at Fred Hutch in CAR T-cell therapy and cellular immunotherapy. CancerFax can help assess whether a patient may be eligible for open studies, subject to institutional review.
Education & Training
Dr. Maloney trained at Whitworth College and Stanford University, completing his MD and PhD in Cancer Biology at Stanford before undertaking residency and fellowship training at Brigham and Women's Hospital and Stanford.
Clinical Experience
Dr. Maloney has spent the majority of his career at Fred Hutchinson Cancer Center, where he rose to full professor, led the cellular immunotherapy programme, and established the Bezos Family Immunotherapy Clinic before transitioning to his current role as Professor Emeritus.
Languages & International
Dr. Maloney conducts consultations in English.
CancerFax can coordinate professional medical interpreter support for international patients consulting at Fred Hutchinson Cancer Center.
CancerFax can coordinate professional medical interpreter support for international patients requiring assistance in other languages.
How CancerFax Helps You Access Dr. David Maloney
CancerFax is a specialist cancer patient-navigation platform. We help international patients prepare structured medical summaries, assess treatment eligibility, and connect directly with Dr. David Maloney's team β with full coordination from initial inquiry to consultation.
Medical Report Review
Free review of your pathology results, imaging, molecular profiling, and treatment history β prepared as a structured clinical summary for Dr. David Maloney's team.
Treatment Eligibility Screening
CancerFax screens your case for eligibility for treatments and clinical programmes available through Dr. David Maloney before you travel, so you arrive with a clear pathway.
Case Submission
We coordinate direct case submission to Dr. David Maloney's department, including all documentation required for clinical review and appointment scheduling.
Appointment & Consultation Coordination
CancerFax manages appointment scheduling with Dr. David Maloney's team, confirming availability and aligning timelines with your travel plans.
Travel, Visa & Logistics Support
We prepare visa invitation letters, provide hospital-proximity accommodation guidance, and coordinate airport transfers for international patients.
Follow-Up & Continuity of Care
After your consultation or treatment, CancerFax facilitates communication between Dr. David Maloney's team and your home oncologist for seamless post-treatment follow-up.
Frequently Asked Questions About Dr. David Maloney
Dr. David G. Maloney is a physician-scientist and Professor Emeritus in the Translational Science and Therapeutics Division at Fred Hutchinson Cancer Center, Seattle. He is internationally recognised for his contributions to CAR T-cell therapy, monoclonal antibody therapy, and hematopoietic cell transplantation for blood cancers, including his instrumental role in the development and clinical testing of rituximab.
Dr. Maloney specialises in haematologic malignancies including lymphoma, non-Hodgkin lymphoma, chronic lymphocytic leukaemia, leukaemia, and multiple myeloma. He has particular expertise in cases where CAR T-cell therapy, cellular immunotherapy, or hematopoietic cell transplantation may be appropriate.
Fred Hutchinson Cancer Center provides patient support services for out-of-region and international patients. CancerFax can assist with coordinating report submission and consultation support. Because Dr. Maloney's current institutional role is listed as Professor Emeritus, patients should confirm his current appointment availability and clinical consultation options directly with Fred Hutch or through CancerFax.
Submit your medical reports through CancerFax using the Send Your Reports button. The CancerFax team will review the documentation, prepare a structured case summary, and coordinate the next steps with Fred Hutchinson Cancer Center, subject to availability and case acceptance.
A second-opinion request can be submitted through CancerFax with the patient's pathology reports, bone marrow biopsy results, molecular profiling, imaging, and prior treatment history. CancerFax will structure the case for submission to Fred Hutch. The final consultation format and timeline depend on the doctor's availability and institutional process.
Dr. Maloney helped develop and deliver CAR T-cell therapies at Fred Hutchinson Cancer Center and served as the founding medical director of the Bezos Family Immunotherapy Clinic, which is dedicated to cellular immunotherapy. He has led multiple clinical trials in CAR T-cell therapy for patients with leukaemia, lymphoma, and myeloma.
Connect with David Maloney Today
Share your medical reports for a free preliminary review. Our patient coordinators will help you understand your options and arrange a direct consultation.
Medical Disclaimer: Information on this page is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making any medical decisions.